BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock OptionsMCAP MediaWire · Oct 8, 2026
BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock OptionsGlobeNewsWire · Oct 8, 2026
Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial AnalysisDefense World · Oct 4, 2026
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent PortfolioMCAP MediaWire · Oct 1, 2026
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent PortfolioGlobeNewsWire · Oct 1, 2026
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq RulesMCAP MediaWire · Sep 30, 2026BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.50 | -$0.52 | Miss |
| May 14, 2026 | -$0.28 | -$0.52 | Miss |
| Mar 24, 2026 | $0.02 | -$0.67 | Miss |
| Nov 13, 2025 | $0.02 | $0.03 | Beat |
| Aug 14, 2025 | $0.32 | -$0.03 | Miss |
| May 12, 2025 | $1.25 | $0.17 | Miss |